Gyre Therapeutics, Inc. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31)
Gyre Therapeutics, Inc. (GYRE) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31) of $30.98 million as of 2017-12-31, per its 10-K filed 2020-02-20.
Discontinued › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1 · last filed 2020-02-20
- 2017-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31) $30.98M.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31) |
|---|---|
| 2017-12-31 | $30.98M 10-K · filed 2020-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |